Cardio-Renal Syndrome Type 2: Epidemiology, Pathophysiology, and Treatment

Seminars in Nephrology

Volumn 32, Issue 1, 2012, Pages 26-30

  Jois, Preeti ^a   Mebazaa, Alexandre ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Cardio renal syndrome 2; Heart failure; Pathophysiology; Therapy

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLYCERYL TRINITRATE; LOOP DIURETIC AGENT; NEUROHORMONE; NEUROTRANSMITTER; PLACEBO; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; VASOPRESSIN; VASOPRESSIN ANTAGONIST;

ACUTE HEART FAILURE; ARTICLE; CARDIORENAL SYNDROME; CARDIORENAL SYNDROME TYPE 2; CENTRAL VENOUS PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DIURETIC THERAPY; DRUG ELIMINATION; HEART DISEASE; HEART FAILURE; HEART OUTPUT; HEMODIALYSIS; HORMONE ACTION; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY PERFUSION; LUNG CONGESTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM EXCRETION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; ULTRAFILTRATION; URINE VOLUME; VASOCONSTRICTION;

CARDIO-RENAL SYNDROME; CARDIOVASCULAR AGENTS; DIURETICS; HEART FAILURE; HUMANS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84857401656     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.11.004     Document Type: Article

References (27)

1. Allender S., Scarborough P., Peto V., et al. European cardiovascular disease statistics: 2008 edition http://www.heartstats.org.uk/uploads/documents%5Cproof30NOV2007.pdf.
2. Roger V.A., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., et al. Heart disease and stroke statistics 2011 update. Circulation 2011, 123:e18-e209.
3. Elixhauser A., Jiang H.J. Hospitalizations for women with circulatory disease, 2003. HCUP statistical brief no. 5 2006, Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb5.pdf.
4. Forman D.E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patient hospitalized with heart failure. J Am Coll Cardiol 2004, 43:61-67.
5. Hillege H.I., Girbes A.R., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102. 203-1.
6. McAlister F.A., Ezekowitz J., Tonelli M., et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004, 109:1004-1009.
7. Ronco C., Haapio M., Andrew A., et al. Cardio-Renal syndrome. J Am Coll Cardiol 2008, 52:1527-1539.
8. Schrier R.W., Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341:577-585.
9. Liu P.P. Cardio-Renal syndrome in heart failure: a cardiologist's perspective. Can J Cardiol 2008, 24:25B-29B.
10. Damman K., Voors A.A., Hillege H., et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 2010, 12:974-982.
11. Drazner M.H., Rame J.E., Stevenson L.W., et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001, 345:574-581.
12. Stein J.H., Neumann A., Marcus R.H. Comparison of estimates of right atrial pressure by physical examination and echocardiography in patients with congestive heart failure and reasons for discrepancies. Am J Cardiol 1997, 80:1615-1618.
13. Schrier R.W. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?. J Am Coll Cardiol 2006, 47:1-8.
14. Liang K.V., William A.W., Greene E.L., Redfield M.M. Acute decompensated heart failure and the cardio-renal syndrome. Crit Care Med 2008, 36:S75-S88.
15. Brewster U.C., Setaro J.F., Perazella M.A. The renin-angiotensin-aldosterone system: cardio-renal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003, 326:15-24.
16. Cadnapaphornchai M.A., Gurevich A.K., Weinberger H.D., et al. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001, 96:122-131.
17. Smith G.L., Vaccarino V., Kosiborod M., et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. J Card Fail 2003, 9:13-25.
18. Owan T.E., Hodge D.O., Herges R.M., et al. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Card Fail 2006, 12:257-262.
19. Gottlieb S.S., Abraham W., Butler J., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002, 8:136-141.
20. Firth J.D., Raine A.E., Ledingham J.G. Raised venous pressure: a direct cause of renal sodium retention in oedema?. Lancet 1988, 1:1033-1035.
21. Salvador D.R., Rey N.R., Ramos G.C., et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005, 3. CD003178.
22. House A., Haapio M., Lassus J., Rinaldo B., Ronco C. Therapeutic strategies for heart failure in cardio-renal syndromes. Am J Kidney Dis 2010, 56:759-773.
23. Kshatriya S., Kozman H., Siddiqui D., et al. The cardio-renal syndrome in heart failure: an evolving paradigm. Am J Med Sci 2010, 340:33-37.
24. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963-1971.
25. Gheorghiade M., Konstam M.A., Burnett J.C., et al. Short-term clinical effects of tolvaptan, and oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 2007, 297:1332-1343.
26. Knight E.L., Glynn R.J., McIntyre K.M., Mogun H., Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 1999, 135:849-855.
27. Costanzo M.R., Guglin M.E., Saltzberg M.T., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007, 49:675-683.